BRPI0519705A2 - composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo - Google Patents

composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo

Info

Publication number
BRPI0519705A2
BRPI0519705A2 BRPI0519705-8A BRPI0519705A BRPI0519705A2 BR PI0519705 A2 BRPI0519705 A2 BR PI0519705A2 BR PI0519705 A BRPI0519705 A BR PI0519705A BR PI0519705 A2 BRPI0519705 A2 BR PI0519705A2
Authority
BR
Brazil
Prior art keywords
compositions
fusion proteins
individual
immune response
stimulating
Prior art date
Application number
BRPI0519705-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Thomas J Powell
Valerian Nakkar
Langzhou Song
William F Mcdonald
Duane D Hewitt
Original Assignee
Vaxinnate Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxinnate Corp filed Critical Vaxinnate Corp
Publication of BRPI0519705A2 publication Critical patent/BRPI0519705A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0519705-8A 2004-12-21 2005-12-21 composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo BRPI0519705A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US63835004P 2004-12-21 2004-12-21
US63825404P 2004-12-21 2004-12-21
US64506705P 2005-01-19 2005-01-19
US65320705P 2005-02-15 2005-02-15
US66687805P 2005-03-31 2005-03-31
US68207705P 2005-05-18 2005-05-18
US74120205P 2005-11-30 2005-11-30
PCT/US2005/046662 WO2006069262A2 (en) 2004-12-21 2005-12-21 Compositions of influenza viral proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI0519705A2 true BRPI0519705A2 (pt) 2009-03-10

Family

ID=36272492

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519705-8A BRPI0519705A2 (pt) 2004-12-21 2005-12-21 composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo

Country Status (9)

Country Link
EP (1) EP1831259A2 (https=)
JP (1) JP2008524261A (https=)
AU (2) AU2005319141B8 (https=)
BR (1) BRPI0519705A2 (https=)
CA (1) CA2593746A1 (https=)
MX (1) MX2007007586A (https=)
NZ (1) NZ556004A (https=)
SG (1) SG160424A1 (https=)
WO (1) WO2006069262A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (en) * 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
US20100068224A1 (en) * 2006-04-24 2010-03-18 Roberto Crea Method for Producing Viral Vaccine and Therapeutic Peptide Antigens
PL2066339T3 (pl) * 2006-09-18 2015-02-27 Univ Arkansas Kompozycje i sposoby zwiększania odpowiedzi immunologicznych
EP1925318A1 (en) * 2006-11-20 2008-05-28 Paul-Ehrlich-Institut Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
WO2009062348A1 (en) 2007-11-14 2009-05-22 Institute Of Microbiology, Chinese Academy Of Sciences Methods for inhibiting influenza virus infection and their drugs
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
MX348663B (es) * 2009-09-08 2017-05-26 Inst Tecnologico Estudios Superiores Monterrey Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009.
JP2013516469A (ja) * 2010-01-06 2013-05-13 ヴァクシネイト コーポレイション 高齢者に保護免疫を提供するための方法及び組成物
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
WO2011120045A1 (en) * 2010-03-26 2011-09-29 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
HK1208355A1 (en) * 2012-11-05 2016-03-04 Georgia State University Research Foundation, Inc. Universal influenza vaccine based on heterologous multiple m2e proteins
RU2571944C1 (ru) * 2014-10-17 2015-12-27 Общество с ограниченной ответственностью "НТфарма" Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
WO2023028661A1 (en) * 2021-09-02 2023-03-09 Ena Respiratory Pty Ltd Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
KR20050114225A (ko) * 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신

Also Published As

Publication number Publication date
NZ556004A (en) 2010-05-28
AU2005319141A1 (en) 2006-06-29
AU2005319141B8 (en) 2010-03-18
SG160424A1 (en) 2010-04-29
JP2008524261A (ja) 2008-07-10
MX2007007586A (es) 2007-12-10
EP1831259A2 (en) 2007-09-12
WO2006069262A3 (en) 2007-02-01
CA2593746A1 (en) 2006-06-29
AU2010200048A1 (en) 2010-01-28
WO2006069262A2 (en) 2006-06-29
AU2005319141B2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
DK1939281T4 (da) Immortaliserede andecellelinjer til virusproduktion
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
BRPI0606479A (pt) composições; proteìnas de fusão; polipepitìdeos; e métodos para estimular uma resposta imune em um indivìduo
BR0212363A (pt) Expressão hìbrida e em tandem de proteìnas de neisseria
NO20063026L (no) Antistoffer
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BRPI0508935A (pt) agonistas de receptor seletivo y4 para intervenções terapêuticas
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
BRPI0515649B8 (pt) Processo para preparação de composições de anticorpo monoclonal altamente concentradas
AR070690A1 (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf (factor de crecimiento de fibroblastos)
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
WO2007047829A3 (en) Novel heterodimeric proteins and uses thereof
IL187168A (en) Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
MX2018005063A (es) Polipéptidos condicionalmente activos.
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
MX2022014162A (es) Proteínas de fusión de la proteína de la espícula del coronavirus estabilizadas.
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
AR042968A1 (es) Anticuerpos de virus anti-dengue composiciones metodos y usos

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.